Healthcare [ 7/13 ] | Biotechnology [ 82/163 ]
NASDAQ | Common Stock
Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types.
Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform.
The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients; and ATRC-501/MAM01, that targets the circumsporozoite protein of Plasmodium falciparum for the treatment of malaria.
Its products in pre-clinical stage include APN-497444, an antibody drug conjugate (ADC) against a novel tumor glycan target; and APN-346958, a CD3 bispecific T-cell engager against an RNA-binding protein target.
It has a collaboration and license agreement with Xencor, Inc. for research, development, and commercialization of novel CD3 bispecific antibodies in oncology; licensing agreement with the Bill & Melinda Gates Medical Research Institute for the development and commercialization of MAM01/ATRC-501 for the prevention of malaria.
The company was incorporated in 2010 and is based in San Carlos, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 14, 23 | -0.39 Increased by +35.00% | -0.38 Decreased by -2.63% |
| Aug 10, 23 | -0.49 Increased by +31.94% | -0.57 Increased by +14.04% |
| May 10, 23 | -0.54 Increased by +16.92% | -0.56 Increased by +3.57% |
| Mar 29, 23 | -0.53 Increased by +32.91% | -0.59 Increased by +10.17% |
| Nov 10, 22 | -0.60 Increased by +18.92% | -0.73 Increased by +17.81% |
| Aug 8, 22 | -0.72 Increased by 0.00% | -0.71 Decreased by -1.41% |
| May 11, 22 | -0.65 Increased by +7.14% | -0.78 Increased by +16.67% |
| Mar 3, 22 | -0.79 Decreased by -25.40% | -0.75 Decreased by -5.33% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 80.00 K Increased by +N/A% | -36.22 M Decreased by -55.48% | Decreased by -45.27 K% Decreased by N/A% |
| Jun 30, 23 | 71.00 K Increased by +N/A% | -19.19 M Increased by +31.55% | Decreased by -27.02 K% Decreased by N/A% |
| Mar 31, 23 | 92.00 K Increased by +N/A% | -18.76 M Increased by +24.72% | Decreased by -20.39 K% Decreased by N/A% |
| Dec 31, 22 | 20.00 K Increased by +N/A% | -20.91 M Increased by +29.14% | Decreased by -104.58 K% Decreased by N/A% |
| Sep 30, 22 | 0.00 Decreased by N/A% | -23.29 M Increased by +14.86% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 22 | 0.00 Decreased by N/A% | -28.03 M Decreased by -5.08% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 22 | 0.00 Decreased by N/A% | -24.92 M Increased by +3.32% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 21 | 0.00 Decreased by N/A% | -29.52 M Decreased by -28.30% | Decreased by N/A% Decreased by N/A% |